Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Biotechnology

Healthcare
$2.29 +0.67%

+$0.02 today

Market cap
$165.63M
Beta
0.35
P/E (TTM)
-1.3
EPS (TTM)
-$1.79
52W Low $1.10High $3.60

Volume 0.81M

Average 0.40M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$115.54M

FY 2025 · Annual

Investing Cash Flow

$133.93M

FY 2025 · Annual

+178.9% YoY

Financing Cash Flow

-$34,000.00

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(100.61M)(42.86M)(52.37M)(102.33M)(121.34M)
Depreciation & Amortization4K169K184K178K(751K)
Deferred Income Tax00000
Stock-Based Compensation922K3.06M6.15M9.64M9.85M
Change in Working Capital298K3.99M3.87M11.65M(5.12M)
Accounts Receivables00000
Inventory00000
Accounts Payables557K552K(261K)4.27M(5.09M)
Other Working Capital(259K)3.43M4.13M7.38M(25K)
Other Non-Cash Items81.42M487K(888K)(5.35M)1.82M
Operating Cash Flow(17.96M)(35.15M)(43.06M)(86.22M)(115.54M)
Capital Expenditures(40K)(161K)(21K)(16K)(88K)
Acquisitions (Net)0(39.35K)3K00
Purchases of Investments(104.08M)(41.51M)(250.63M)(170.73M)(38.06M)
Sales of Investments080.86M78.98M218.77M172.08M
Other Investing Activities039.35K000
Investing Cash Flow(104.12M)39.19M(171.67M)48.03M133.93M
Debt Repayment0030M(739K)0
Common Stock Issued168.56M3.79M121.9M7.94M39K
Common Stock Repurchased000(41K)(73K)
Dividends Paid00000
Other Financing Activities1.88M115K(151K)(230K)0
Financing Cash Flow200.47M3.91M151.75M6.93M(34K)
Effect of Forex Changes00000
Net Change in Cash78.39M7.94M(62.98M)(31.26M)18.36M
Free Cash Flow(18M)(35.31M)(43.09M)(86.23M)(115.63M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$121.3M
+ D&A-$751.0K
+ Stock-Based Comp$9.9M
+ Deferred Tax$0
- Working Capital-$5.1M
+ Other Non-Cash$1.8M
= Operating Cash Flow-$115.5M
- Capex-$88.0K
= Free Cash Flow-$115.6M

Analysis

FY2025 free cash flow is -$115.6M. FCF conversion is 95.3% of net income. Operating cash flow was -$115.5M, with capex of -$88.0K. The largest bridge item is Stock-Based Comp at $9.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportSep 16, 2026
S-8S-8 filingAug 12, 2026
8-KCurrent reportAug 12, 2026
10-QQuarterly reportAug 12, 2026
4Statement of changes in beneficial ownershipJun 17, 2026

Does ABOS generate free cash flow?

Acumen Pharmaceuticals, Inc. (ABOS) generated -$115.63M of free cash flow in fiscal 2025.

How much operating cash flow does ABOS produce?

Operating cash flow was -$115.54M, before capital expenditures of $88,000.00.